Trial
NCT00708721
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Utah
Collaborators
Genzyme, a Sanofi Company
Condition
Cancer
Intervention
Clofarabine
Why stopped
Data analysis revealed sufficient data for safety and efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-01